Pfizer Inc.
ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
Last updated:
Abstract:
The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
Status:
Application
Type:
Utility
Filling date:
8 Aug 2019
Issue date:
2 Apr 2020